A Porous Ni(II)-MOF for CO 2 Cycloaddition and Protective Effect on Type-II Diabetes via Reducing Cell ROS Production an
- PDF / 2,502,934 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 6 Downloads / 182 Views
(0123456789().,-volV)(0123456789(). ,- volV)
ORIGINAL PAPER
A Porous Ni(II)-MOF for CO2 Cycloaddition and Protective Effect on Type-II Diabetes via Reducing Cell ROS Production and Cell Apoptosis Jie Lai1 • Yang Han2 • Hong-Mei Li2 • Jia Wang1 • Chun-Ling Wang1 • Lin Suo3 • Ying Sun1 Kai-Liang Wang2
•
Received: 8 November 2019 Springer Science+Business Media, LLC, part of Springer Nature 2019
Abstract The solvothermal reaction of the 5-methoxyisophthalic acid (H2mia) ligand and Ni(NO3)26H2O affords a new highly porous metal–organic framework {[Ni2(mia)2(H2O)](DMF)4}n (1). The structural composing of the as-prepared complex 1 was determined via the elemental analysis and its structural arrangement was probed via the single crystal analysis. Due to its large porous volume along with the abundant open metal sites, complex 1 could be used as a good catalyst for cyclic addition of carbon dioxide to ring oxides under mild conditions of 1 bar carbon dioxide for high yield synthesis of cyclocarbonates. The protective effect of the complex 1 on Type-II diabetes was further evaluated. The inhibitory effect of compound on pancreatic b-cell apoptosis and cell cycle arrest was determined via Annexin V-FITC/PI assay. The oxidative stress state influenced by compound was determined by DCFH-DA assay. The results obtained from molecular docking and pose scoring software exhibited a possible binding mode of the compound binding to Bcl2, which might provide potential regulation mechanisms for the compound. Keywords Ni(II)-complex Porous framework CO2 sorption CO2 cycloaddition Molecular docking
Introduction Diabetes mellitus (DM) is getting the attention of more and more researchers. The prevalence of DM is continuously increasing in recent years, and the newest reports showed that the DM incidence will rise to about 550 million in the future 10 years [1, 2]. Based on the cause of diabetes, the DM can be divided into Type-I and Type-II diabetes mellitus. Type-II diabetes mellitus is a chronic metabolic disease, which is led by the deficiencies in insulin secretion and insulin action [3, 4]. According to current research, the Jie Lai and Yang Han contributed equally to this work. & Kai-Liang Wang [email protected] 1
Department of Cadres’ Ward, Emergency General Hospital, Beijing, China
2
Department of Endocrine, Emergency General Hospital, Beijing, China
3
Department of Pharmacy, Emergency General Hospital, Beijing, China
pathogenesis of diabetes is mainly owing to the absolute or relative deficiency of insulin and insulin resistance. The therapeutic drugs can also be divided into six categories according to their mechanism of action: insulin and insulin analogues, insulin-sensitive drugs, insulin-promoting drugs, a-glucosidase inhibitors, new hypoglycemic drugs and traditional Chinese medicines. Currently, the clinical widely used drugs for DM suffer from many disadvantages such as the Metformin often causes adverse reactions in the gastrointestinal tract [5]. Thus, it is needed to explore the mechanism
Data Loading...
